| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | deferiprone (Ferriprox®) |
| Formulation | 500 mg and 1000 mg film-coated tablet; 100 mg/ml oral solution |
| Reference number | 3166 |
| Indication | In combination with another chelator for patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction |
| Company | Swedish Orphan Biovitrum Ltd |
| BNF chapter | Nutrition & blood |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 10/11/2016 |